CDSCO Compliance 2026: What Pharma Manufacturers Should Check

India’s pharmaceutical industry is operating in an increasingly regulated environment. For manufacturers, maintaining a valid manufacturing licence is no longer enough. Regulators are placing greater emphasis on Good Manufacturing Practices (GMP), documentation, quality systems, pharmacovigilance, data integrity, and the ability of a company to demonstrate that its processes remain under control.

For pharma manufacturers, 2026 is therefore less about simply “passing an inspection” and more about building a compliance system that works every day.

The Central Drugs Standard Control Organisation (CDSCO) continues to strengthen regulatory oversight, while recent regulatory activity has placed additional attention on areas such as Schedule M, pharmacovigilance, sampling practices, product quality, and regulatory documentation. CDSCO's 2026 circulars include a June 2026 communication concerning the implementation of the pharmacovigilance system under Schedule M.

So, what should pharmaceutical manufacturers check in 2026?

Let's look at the most important areas.

What Does CDSCO Compliance Mean for Pharma Manufacturers?

CDSCO compliance refers to the manufacturer's ability to meet the applicable requirements under India's pharmaceutical regulatory framework, including the Drugs and Cosmetics Act, Drugs and Cosmetics Rules, applicable licensing requirements, GMP provisions, and other relevant regulatory requirements.

In practical terms, compliance means being able to demonstrate that:

• The manufacturing facility is appropriately licensed.

• Manufacturing activities follow approved procedures.

• Products meet established quality specifications.

• Personnel are trained and qualified for their responsibilities.

• Equipment and processes are appropriately controlled.

• Manufacturing and testing records are complete and traceable.

• Deviations, complaints, and changes are investigated and controlled.

• Product quality is reviewed periodically.

• Appropriate pharmacovigilance systems are maintained where applicable.

In other words, pharmaceutical regulatory compliance is not one document or one certificate. It is a complete system connecting manufacturing, quality control, documentation, and post-market responsibilities.

1. Start With Your Manufacturing Licence and Product Permissions

The first compliance checkpoint is basic but critical: are your manufacturing activities properly authorised?

A manufacturer should periodically verify that its licences, approved products, manufacturing premises, dosage forms, and applicable permissions accurately reflect what is actually being manufactured.

This becomes particularly important when a company:

• Adds a new dosage form

• Introduces a new product

• Changes manufacturing equipment

• Expands production capacity

• Changes manufacturing locations

• Makes significant process changes

• Adds or modifies manufacturing arrangements

A mismatch between the approved regulatory position and actual manufacturing activities can create unnecessary compliance risk.

Manufacturers should therefore maintain an updated regulatory master file covering licences, permissions, product information and significant regulatory correspondence.

2. Revised Schedule M Should Be on Every Manufacturer's Compliance Radar

One of the biggest areas manufacturers need to understand is the Revised Schedule M.

The revised Schedule M framework places strong emphasis on modern pharmaceutical quality systems and GMP principles. It goes beyond simply keeping a clean production area. Manufacturers need systems that demonstrate consistent control over manufacturing and quality activities.

Key areas include:

• Quality Assurance

• Quality Control

• Pharmaceutical Quality System

• Quality Risk Management

• Personnel and training

• Premises and equipment

• Production controls

• Documentation

• Validation and qualification

• Complaints and recalls

• Self-inspection

• Batch release

• Product quality review

The important point is that compliance should not be treated as a one-time upgrade.

A manufacturer may have excellent infrastructure, but if procedures are not followed consistently or records do not accurately reflect what happened, the compliance system remains vulnerable.

3. Build a Pharmaceutical Quality System That Actually Works

A strong Pharmaceutical Quality System (PQS) should connect the different parts of a manufacturing operation.

Think of it as the framework that answers five simple questions:

What should happen?
Approved SOPs and specifications define the expected process.

Who is responsible?
Roles, responsibilities, and authorisations must be clearly established.

What actually happened?
Batch records, laboratory records, and other documentation provide evidence.

What happens when something goes wrong?
Deviations, investigations, and CAPA provide a controlled response.

How does the company improve?
Change control, trend analysis, audits, and management review support continual improvement.

A quality system becomes meaningful when these processes work together rather than existing as separate documents.

4. Check Premises, Equipment and Environmental Controls

Manufacturing compliance is also closely connected to the physical condition and qualification status of the facility.

Manufacturers should review whether:

• Production areas are appropriately designed and maintained.

• Material and personnel movement is controlled.

• Cleaning procedures are established and followed.

• Equipment is qualified and maintained.

• Calibration schedules are current.

• Environmental monitoring is performed where applicable.

• Utilities are appropriately controlled.

• Preventive maintenance is documented.

• Storage conditions are monitored and recorded.

For sterile or specialised manufacturing operations, the requirements can be considerably more detailed.

The goal is not simply to make the facility “look compliant” before an inspection. The facility should remain controlled throughout routine operations.

5. Documentation Is Evidence of Compliance

One of the most important principles in pharmaceutical manufacturing is simple:

If an activity is required to be performed and documented, the record should clearly demonstrate that it happened.

This is why pharmaceutical documentation remains one of the most important areas during regulatory inspections.

Manufacturers should pay particular attention to:

• Standard Operating Procedures

• Batch Manufacturing Records

• Batch Packing Records

• Laboratory records

• Specifications

• Test methods

• Equipment logbooks

• Cleaning records

• Calibration records

• Training records

• Deviation records

• CAPA records

• Change-control records

• Complaint records

• Recall documentation

• Validation reports

Records should be complete, legible, traceable, and contemporaneous.

Poor documentation can create a compliance problem even when the underlying manufacturing activity was performed correctly.

6. Strengthen Data Integrity Across Manufacturing and QC

Modern data integrity is not limited to electronic software.

It applies to the reliability and traceability of information throughout the product lifecycle.

Manufacturers should ask:

Can we demonstrate who created the record, when it was created, what was changed, and why?

This applies to laboratory results, production records, electronic systems, logbooks, and other regulated information.

Important controls may include:

• User access management

• Audit trails

• Controlled data changes

• Backup procedures

• Record retention

• Review of critical electronic data

• Appropriate segregation of responsibilities

Data should accurately represent the activity that actually occurred.

7. Review Validation and Qualification Status

Another important part of CDSCO GMP requirements is ensuring that critical processes and equipment remain appropriately qualified and validated.

Depending on the manufacturing operation, this may include:

• Equipment qualification

• Process validation

• Cleaning validation

• Analytical method validation

• Computerised system validation

• Utilities qualification

• Validation of critical manufacturing processes

Validation should not become a document-generation exercise.

The objective is to provide documented evidence that a process, system or piece of equipment consistently performs as intended.

Manufacturers should also establish procedures for determining when requalification or revalidation is required following significant changes.

8. Don't Ignore Deviations, CAPA and Change Control

A manufacturing site with zero deviations may sound ideal.

In reality, regulators are interested in whether a company can identify, investigate, and control problems effectively.

A mature quality system should have a defined process for:

Deviation Management

When something does not happen according to an approved procedure, the event should be documented and assessed appropriately.

Root Cause Analysis

The investigation should attempt to identify the actual underlying cause rather than simply assigning blame.

CAPA

Corrective and Preventive Actions should address the identified problem and reduce the possibility of recurrence.

Change Control

Changes to processes, equipment, materials, documents, or systems should be evaluated before implementation where applicable.

The objective is straightforward: identify problems early, understand why they happened, and prevent them from becoming recurring quality issues.

9. Keep Quality Control Independent and Effective

The Quality Control function plays a central role in demonstrating that pharmaceutical products meet established specifications.

Manufacturers should review:

• Raw-material testing

• Packaging-material testing

• In-process testing

• Finished-product testing

• Stability studies

• Reference and retention samples

• Laboratory equipment

• Analytical methods

• Out-of-specification investigations

• Laboratory documentation

An effective QC system is not simply about producing a certificate of analysis.

It should provide confidence that the test results are scientifically sound, traceable, and representative of the material or product being evaluated.

10. Product Quality Review Should Be a Management Tool

Product Quality Review (PQR) should not be treated as another annual document prepared only because it is required.

A meaningful review can help manufacturers identify trends involving:

• Batch failures

• Deviations

• Complaints

• Returns

• Rejected batches

• Stability results

• Changes

• Recurring manufacturing issues

• Yield variations

When analysed properly, PQR can reveal problems before they become major regulatory or commercial issues.

For management, it can also provide a useful picture of whether manufacturing processes remain consistently controlled.

11. Pharmacovigilance Is Becoming Increasingly Important

Manufacturers and Marketing Authorisation Holders should also pay attention to pharmacovigilance and post-marketing safety responsibilities applicable to their products.

CDSCO's current regulatory activity shows continued attention to pharmacovigilance. In June 2026, CDSCO published a communication concerning the implementation of the pharmacovigilance system under Schedule M.

Read also - 5 Ways Professional Marketing Can Grow Your Pharma Franchise

The broader pharmacovigilance framework involves processes for receiving, evaluating, documenting, and reporting adverse events and maintaining appropriate safety information.

Manufacturers should therefore establish clear responsibilities for:

• Receiving product complaints and adverse-event information

• Recording safety information

• Evaluating reports

• Escalating serious safety information

• Maintaining appropriate records

• Supporting regulatory reporting

• Conducting required follow-up

CDSCO's pharmacovigilance guidance also describes areas such as the Pharmacovigilance System Master File, Individual Case Safety Reports, Periodic Safety Update Reports, quality management systems, and pharmacovigilance audits.

12. Prepare for Inspection Before You Receive the Notice

One of the most effective approaches to CDSCO inspection readiness is to stop treating inspection preparation as a last-minute activity.

Instead, manufacturers should conduct periodic internal assessments.

A practical self-audit can look like this:

Area	What to Check
Licensing	Are licences and permissions current?
GMP	Are applicable Schedule M requirements implemented?
SOPs	Are procedures current and actually followed?
Training	Are employees trained and training documented?
Equipment	Are qualification, calibration, and maintenance records current?
Production	Are batch records complete and traceable?
QC	Are testing records and investigations controlled?
Validation	Are critical processes appropriately validated?
Data	Are records secure, accurate, and traceable?
CAPA	Are corrective actions effective and closed on time?
Complaints	Are complaints investigated and trended?
Pharmacovigilance	Are applicable safety processes established?

The key is to verify the actual practice, not just the paperwork.

13. Common Compliance Gaps Manufacturers Should Watch

Some compliance weaknesses are surprisingly basic.

For example:

• The SOP says one thing, but employees do another.

• The equipment is qualified, but maintenance records are incomplete.

• A deviation is closed, but the root cause was never properly established.

• Training is recorded, but employee understanding was never evaluated.

• Data exists, but the audit trail or change history is not adequately controlled.

• Complaints are logged individually, but nobody analyses recurring trends.

These gaps can develop gradually in a growing organisation.

That is why routine internal audits and management review are so valuable.

For the latest information on approved new drugs, manufacturers can refer to the official CDSCO Approved New Drugs resources.

What Should Pharma Manufacturers Check First in 2026?

If a manufacturer wants to perform a practical compliance review, start with these ten questions:

1. Are all manufacturing licences and permissions current?

2. Has the facility completed a meaningful Schedule M compliance gap assessment?

3. Are critical SOPs current and consistently followed?

4. Are equipment qualification and calibration records up to date?

5. Are batch manufacturing and testing records complete?

6. Are deviations investigated using appropriate root-cause analysis?

7. Are CAPA actions effective and closed within defined timelines?

8. Is data integrity adequately controlled?

9. Are complaints, recalls, and applicable pharmacovigilance activities properly managed?

10. Can the company demonstrate compliance through records rather than verbal explanations?

If several answers are uncertain, the manufacturer should consider conducting a structured internal compliance audit.

What Does CDSCO Compliance Mean for Third-Party Pharma Manufacturing?

Compliance becomes particularly important when a company outsources manufacturing.

Before selecting a third-party manufacturer, pharma companies should evaluate more than product price.

They should look at:

• Manufacturing licences

• Applicable GMP status

• Product manufacturing permissions

• Quality-control capabilities

• Batch documentation

• Testing arrangements

• Stability support

• Change-control procedures

• Complaint handling

• Regulatory documentation

• Manufacturing capacity

• Quality agreement provisions

A reliable third-party pharmaceutical manufacturing partner should be able to provide appropriate documentation and demonstrate that quality is built into the manufacturing process.

For companies developing or expanding a product portfolio, this can make regulatory diligence an important part of supplier selection.

Compliance in 2026: Think Beyond the Inspection

The biggest change in mindset is simple.

Compliance should not be something a pharmaceutical company prepares for when an inspector arrives.

It should be part of everyday manufacturing.

When quality systems, documentation, production, laboratory operations, training, validation, pharmacovigilance, and management review work together, inspection readiness becomes a natural result of good operations.

For pharmaceutical companies, this approach can also support better consistency, stronger supplier relationships, improved traceability, and greater confidence in the products reaching the market.

Build Compliance Into Your Manufacturing Strategy

For pharmaceutical manufacturers, 2026 is a good time to move from a document-focused approach to a quality-focused compliance culture.

The strongest manufacturing operations are not those that simply prepare well for an inspection. They are the ones where GMP, documentation, quality control, validation, data integrity, and safety monitoring are integrated into everyday work.

For companies looking for a reliable manufacturing partner, Monark Biocare provides pharmaceutical manufacturing and business-support solutions designed around the requirements of modern pharma operations.

Find the right solution with our third-party pharmaceutical manufacturing, pharmaceutical tablet manufacturing, PCD Pharma Franchise in India, and broader pharmaceutical product range to understand how we can support your pharmaceutical business requirements.

Compliance Is the Foundation. Growth Is the Goal.

Monark Biocare

• Plot No. 201, HSIIDC, Alipur, Barwala, Haryana, India

• Email: monarkbiocare@gmail.com

• Phone: +91-9855986633 | +91-9023256719 | +91-9888656719

Related Source Data

This article is based on publicly available regulatory information and guidance relevant to pharmaceutical manufacturing compliance in India. Manufacturers should always verify the latest applicable notifications, circulars, gazette publications, and regulatory requirements before making compliance decisions.

Source	Relevant Information
Central Drugs Standard Control Organisation (CDSCO)	Regulatory framework, drug manufacturing oversight, notifications, circulars, and compliance updates
Drugs & Cosmetics Act, 1940	Primary legal framework governing drugs and cosmetics in India
Drugs & Cosmetics Rules, 1945	Regulatory requirements applicable to pharmaceutical manufacturing and licensing
Schedule M – GMP Requirements	Requirements relating to Good Manufacturing Practices, quality systems, premises, equipment, production and documentation
CDSCO Schedule M Updates	Regulatory communications and implementation-related information concerning Revised Schedule M
CDSCO Pharmacovigilance Resources	Guidance and regulatory information concerning post-marketing drug safety and pharmacovigilance
CDSCO SUGAM Portal	Online regulatory submission and permission-related services for applicable pharmaceutical activities

Key Regulatory Areas Covered

The source material is particularly relevant to:

GMP & Schedule M • Pharmaceutical Quality Systems • Quality Assurance • Quality Control • Validation & Qualification • Data Integrity • Documentation • CAPA • Change Control • Product Quality Review • Pharmacovigilance • Regulatory Inspection Readiness

Important: Regulatory requirements can change through new notifications, amendments, and circulars. Pharmaceutical manufacturers should consult the latest official CDSCO and applicable government publications before relying on any regulatory interpretation.

Regulatory Source: Central Drugs Standard Control Organisation (CDSCO) (cdsco.gov.in), Ministry of Health & Family Welfare, Government of India.

Frequently Asked Questions About CDSCO Compliance 2026

01. What is CDSCO compliance?

CDSCO compliance means meeting the applicable Indian regulatory requirements governing pharmaceutical manufacturing, product quality, licensing, GMP, documentation, safety monitoring, and related activities.

02. What are the major CDSCO requirements for pharma manufacturers?

Key areas include applicable manufacturing licences, GMP compliance, Schedule M requirements, quality control, documentation, validation, equipment qualification, data integrity, deviation and CAPA management, complaints, and applicable pharmacovigilance responsibilities.

03. What is Revised Schedule M?

Revised Schedule M is the updated GMP framework under India's Drugs and Cosmetics Rules that establishes requirements covering pharmaceutical manufacturing and quality systems.

04. What does CDSCO check during an inspection?

Depending on the scope of the inspection, regulators may review manufacturing practices, premises, equipment, documentation, laboratory controls, validation, quality systems, deviations, complaints, and other applicable regulatory requirements.

05. How can a pharma manufacturer prepare for a CDSCO inspection?

The best approach is continuous inspection readiness. Manufacturers should conduct internal audits, maintain accurate documentation, review Schedule M compliance, close CAPAs effectively, and ensure employees follow approved procedures.

06. Is pharmacovigilance part of pharmaceutical compliance?

Yes. Applicable manufacturers and Marketing Authorisation Holders need appropriate systems for handling and reporting drug-safety information. CDSCO's current guidance and regulatory communications place significant emphasis on pharmacovigilance systems.

Disclaimer: 

This article is intended for general informational purposes and does not constitute legal, regulatory, medical, or professional advice. CDSCO regulations, GMP requirements, Schedule M provisions, and pharmaceutical compliance standards may be revised from time to time. Manufacturers and other stakeholders should verify the latest applicable requirements from official regulatory sources before taking any action. Monark Biocare makes no guarantee regarding the completeness or applicability of the information to a specific business or manufacturing situation.